News Updates - Voyageur Pharmaceuticals

NEWS

September 8, 2026

Voyageur Pharmaceuticals Achieves First Milestone on Feasibility Study for Iodine Production; Secures USD $1 Million Payment

CALGARY, Alberta – September 8, 2026 – Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) (“Voyageur” or the...

Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker

FOR IMMEDIATE RELEASE CALGARY, Alberta – July 17, 2026 – Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF)...

Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility

FOR IMMEDIATE RELEASE CALGARY, Alberta – June 23, 2026 – Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF)...

Voyageur Pharmaceuticals Evaluating Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility, a Multi-Phase Investment Expected to Generate Significant Economic Impact and High-Skilled Jobs; Competitive Site Selection Process Underway

CALGARY, Alberta – June 18, 2026 – Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) (“Voyageur” or the...

Voyageur Pharmaceuticals Ltd. Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support at Frances Creek Barite Project

Calgary, Alberta – June 10, 2026 – Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the “Company” or “Voyageur”) announces the...

Voyageur Announces Closing of Non-Brokered Private Placement Pursuant to Listed Issuer Financing Exemption

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED...

12 3…9

Next ›

¹ SGS PEA
^1.1 SGS PEA Item 1.17 (p. 16) and Table 21-6 (p. 174); USP assay Table 1-2 (p. 10–11).
² Global contrast media market projected to reach $13.9B by 2033, at a CAGR of 8.4%. Source: Grand View Research, “Contrast Media Market Size And Share Report, 2026-2033.”